Cargando...
Oncological benefits of portal vein embolization for patients with hepatocellular carcinoma
Portal vein embolization (PVE) for hepatocellular carcinoma (HCC) was first introduced in 1986 and has been continuously developed throughout the years. Basically, PVE has been applied to expand the indication of liver resection for HCC patients of insufficient future liver remnant. Importantly, PVE...
Guardado en:
| Publicado en: | Ann Gastroenterol Surg |
|---|---|
| Autores principales: | , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8164464/ https://ncbi.nlm.nih.gov/pubmed/34095718 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ags3.12414 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|